Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Instil Bio Inc.(TIL)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for TIL
10/23/2026: TIL (1-star) is currently NOT-A-BUY. Pass it for now.
Instil Bio Inc. is a clinical-stage biotechnology company centered on developing novel cell therapies for solid tumors. While the company possesses proprietary technology and a specialized manufacturing facility, it has struggled with clinical execution and the operational complexity of its cell-therapy platform. Its current strategy involves pivoting toward identifying and acquiring external therapeutic assets to drive future growth. Key risks include intense competition from better-capitalized peers, significant regulatory challenges, and the high-risk nature of its pipeline. The stock is best suited for speculative investors who are monitoring the company’s ability to successfully execute its new acquisition-based development strategy without exhausting its remaining cash reserves.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | The company's current stage and lack of commercial products make it a high-risk, speculative biotech play rather than a traditional growth stock. |
| Momentum investor | Weak fit | The stock lacks sustained upward momentum and typically requires a strong positive clinical signal to attract this style. |
| Value investor | Weak fit | The company's lack of revenue and persistent losses make it unsuitable for traditional value-based analysis. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses all capital on R&D. |
| Low-risk investor | Weak fit | The stock's high volatility and clinical-stage risks are inherently unsuitable for low-risk strategies. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks in the clinical stage frequently experience extreme price swings based on trial updates or funding news. |
| Valuation risk | High | The absence of commercial products makes it difficult to anchor valuation to traditional fundamentals. |
| Competition risk (Oncology/Cell Therapy) | High | Established competitors like Iovance have more advanced products, putting immense pressure on Instil Bio to differentiate. |
| Business quality | Medium | While the platform has technical merit, the company's history of operational adjustments limits current business quality metrics. |
| Dividend income | Low / none | There is no income generation for investors from this security. |
| Execution risk | High | The company must successfully pivot toward external innovation and capital deployment to survive. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 549.91% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 38.66M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 34.7K shares | Beta 1.94 | 52 Weeks Range 5.62 - 20.11 | Updated Date 10/23/2026 |
52 Weeks Range 5.62 - 20.11 | Updated Date 10/23/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.43 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Oncology Research & Development | Advancement of TIL and CoStAR platform therapies through clinical trials. | The company currently makes no profit; it burns cash to research cancer drugs and hopes for future clinical success. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 66.81M | Price to Sales(TTM) 54248.82 |
Enterprise Value 66.81M | Price to Sales(TTM) 54248.82 | ||
Enterprise Value to Revenue 43213.95 | Enterprise Value to EBITDA 0.62 | Shares Outstanding 6.78M | Shares Floating 3.66M |
Shares Outstanding 6.78M | Shares Floating 3.66M | ||
Percent Insiders 6.56 | Percent Institutions 62.5 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.